| Literature DB >> 30191971 |
Mahdi Rivandi1, Alireza Pasdar1,2,3, Leila Hamzezadeh2,4, Amir Tajbakhsh1,4, Sima Seifi5, Mehrdad Moetamani-Ahmadi5, Gordon A Ferns6, Amir Avan5,7.
Abstract
Long noncoding RNAs (lncRNAs) consist of 200 nucleotide sequences that play essential roles in different processes, including cell proliferation, and differentiation. There is evidence showing that the dysregulation of lncRNAs promoter of CDKN1A antisense DNA damage-activated RNA (PANDAR) leads to the development and progression in several cancers including colorectal cancer, via p53-dependent manner. This suggests that these lncRNAs may be of value as prognostic indices and a therapeutic target, as a high expression of lncRNAs PANDAR is associated with poor prognosis. Furthermore, modulating lncRNAs PANDAR has been reported to induce apoptosis and inhibit the tumor growth through modulation of cell cycle and epithelial-mesenchymal transition (EMT) pathway. The aim of the current review was to provide an overview of the prognostic and therapeutic values of lncRNAs PANDAR in colorectal cancer.Entities:
Keywords: colorectal cancer; lncRNAs promoter of CDKN1A antisense DNA damage-activated RNA (PANDAR); long noncoding RNAs (lncRNAs); prognostic biomarker; therapeutic target
Year: 2018 PMID: 30191971 DOI: 10.1002/jcp.27136
Source DB: PubMed Journal: J Cell Physiol ISSN: 0021-9541 Impact factor: 6.384